Clinical Research Directory
Browse clinical research sites, groups, and studies.
Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea
Sponsor: Sanofi
Summary
This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\*. \*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.
Key Details
Gender
All
Age Range
6 Weeks - 55 Years
Study Type
OBSERVATIONAL
Enrollment
706
Start Date
2026-07-01
Completion Date
2027-11-23
Last Updated
2026-07-29
Healthy Volunteers
Yes
Interventions
Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Locations (9)
Investigational Site Number: 410009
Busan, South Korea
Investigational Site Number: 410011
Daegu, South Korea
Investigational Site Number: 410003
Goyang, South Korea
Investigational Site Number: 410008
Gwangju, South Korea
Investigational Site Number: 410010
Hanam, South Korea
Investigational Site Number: 410006
Iksan, South Korea
Investigational Site Number: 410005
Seongnam, South Korea
Investigational Site Number: 410004
Seoul, South Korea
Investigational Site Number: 410007
Seoul, South Korea